Slide 1: Pfizer Pflash: A Spotlight on Antibody Drug Conjugates (ADCs)
Pfizer Pflash: A Spotlight on Antibody Drug Conjugates (ADCs) Classified – Confidential Presentation intended 1 for the investment community
Slide 2: Forward-Looking Statements and Other Notices
Forward-Looking Our discussions during this presentation will include forward-looking statements about, among other topics, Pfizer Oncology and Pfizer’s These statements may be affected by underlying assumptions that may prove inaccurate or incomplete, and are subject to risks, uncertainties Stateme
Slide 3: Today's Speakers
Today’s Speakers Hosted by Francesca DeMartino Megan O’Meara, MD Scott Peterson, PhD Jeff Settleman, PhD Chief Investor Head, Oncology Early Head, ADC Discovery Chief Scientific Officer Clinical Development Oncology R&D Relations Officer 3
Slide 4: Pfizer Oncology Strategy
Pfizer Oncology Strategy Accelerate breakthroughs that help people with cancer live b etter and longer lives Modality Focus Therapeutic Area Focus Enabled by Deep Technical Expertise Building on Established Presence Unique ability to combine and adapt modalities to improve outcomes Deepen our abi
Slide 5: Pfizer Oncology: Combined Core Strengths Create a Global Leader in ADC Development
Pfizer Oncology: Combined Core Strengths Create a Global Leader in ADC Development Legacy Pfizer Legacy Seagen Small Molecules & Medicinal Chemistry ADC Development Protein Engineering & Antibody Design ADC Discovery & Design Oncology Global Footprint Industry Leading Resources & ADC Platform Manufa
Slide 6: ADC Design: Delivering Cytotoxic Molecules Selectively to Cancer Cells
ADC Design: Delivering Cytotoxic Molecules Selectively to Cancer Cells Antibody Selectively binds to target on cancer cells Payload Drug that kills cancer cells Linker Tethers payload to antibody ADC, antibody drug conjugate 6
Slide 7: Mechanism of Action for Vedotin (MMAE) ADCs
Mechanism of Action for Vedotin (MMAE) ADCs ADC, antibody drug conjugate; APC, antigen-presenting cell; MHC, major histocompatibility complex; MMAE, monomethyl auristatin E; TCR, T-cell receptor †Additional mechanisms of action and their potential to complement the direct cytotoxicity of some MMAE-b
Slide 8: Immunogenic Cell Death Provides Rationale for Combination of ADCs with Immune Checkpoint Inhibitors
Immunogenic Cell Death (ICD) Provides Rationale for Combination of ADCs with Immune Checkpoint Inhibitors T cell responses can be augmented by PD-1/L1 inhibitors PD-1/PD-L1 Interaction Prevents T cells from killing tumor cells PD-1/PD-L1 Blockade Allows T cells to kill tumor cells ADC, antibody drug
Slide 9: Vedotin ADCs Demonstrate Potential Clinical Synergy with Anti-PD-1
Vedotin ADCs Demonstrate Potential Clinical Synergy with Anti-PD-1 PADCEV TIVDAK PADCEV TIVDAK 23.3 DoR (months) 68% ORR (%) 13.2 13.8 45% 38% 18% 5.3 ADC ADC + ADC ADC + ADC ADC + ADC ADC + monotherapy anti-PD-12 1 monotherapy anti-PD-14 3 monotherapy1 anti-PD-15 monotherapy anti-PD-14 3 (Phase 1b/
Slide 10: PADCEV + Anti-PD-1 Combination Provides Statistically Significant, Clinically Meaningful Benefit in Phase 3 Study
PADCEV + Anti-PD-1 Combination Provides Statistically Significant, Clinically Meaningful Benefit in Phase 3 Study of Frontline Treatment for Locally Advanced or Metastatic Urothelial Carcinoma Updated results from oral presentation of study EV-302 at 2025 ASCO GU1 PADCEV Chemotherapy + Anti-PD-1 Med
Slide 11: Pfizer's Substantial Footprint on the Landscape of Currently Approved ADCs
Pfizer’s Substantial Footprint on the Landscape of Currently Approved ADCs 12 FDA approved ADCs, 5 of which are Pfizer products ● and 1 more employs licensed Seagen technology ● 1 additional Pfizer product (disitamab vedotin) approved in China Disitamab vedotin (Approved in China) Urothelial cancer
Slide 12: Industry Leading ADC Portfolio Advancing Pipeline With Novel Targets & Diversified Linker-Payload Technologies
Industry Leading ADC Portfolio Advancing Pipeline With Novel Targets & Diversified Linker-Payload Technologies Select Vedotin Select ADCs Next Gen Auristatin ADCs With Novel FDA-Approved ADCs in Employing TOPO1 ADCs With Potentially Payload Vedotin ADCs Development Inhibitor Payloads Improved Tolera
Slide 13: Pfizer is Aiming to Create the Next Frontier in ADCs
Pfizer is Aiming to Create the Next Frontier in ADCs POTENTIAL FUTURE CURRENT PAYLOADS MoA DEVELOPMENT OPPORTUNITIES PAYLOADS Next gen cytotoxics Tubulin (MMAE) • Diversify MoAs to improve activity and tolerability • Address resistance to current ADC payloads Immune agonists DNA damage (TOPO1) • Inc
Slide 14: Q&A Session
Q&A Session Hosted by Francesca DeMartino Megan O’Meara, MD Scott Peterson, PhD Jeff Settleman, PhD Chief Investor Head, Oncology Early Head, ADC Discovery Chief Scientific Officer Relations Officer Clinical Development Oncology R&D 14